Medicolegal considerations with intravenous tissue plasminogen activator in stroke: a systematic review.
Conclusion. Physicians and hospitals are at an increased risk of litigation in patients with AIS when in IV-tPA is being considered for treatment. While majority of the cases litigated were cases where tPA was not administered, only about 1 in 20 cases was litigated when complications occurred.
PMID: 24083048 [PubMed]
Source: Stroke Research and Treatment - Category: Neurology Tags: Stroke Res Treat Source Type: research
More News: Databases & Libraries | Ischemic Stroke | Legislation | Malpractice | Neurology | Stroke | Study | Thrombolytic Therapy | Thrombosis